The efficacy argument is based upon 16 week endpoints but MDs don't listen to PIs - they listen to their peers at the Congresses where a landslide of data shows that although APR works slower than biologics, there is no statistical difference in efficacy after week 24. Then from week 24 until forever the patient gets no needles jabbed into flesh, no needles jabbed in to arms for liver testing, no cancers, no yeast infections, no respiratory tract infections, no CNS side effects, no blood poisoning, no cardiac death, etc. One of of five does get some lose stools the first 5-10 days and some may lose weight. 1.0% vs 0.8% "reported" depression.
Efficacy is not a question with MDs. The competition hits that all the time and it's only made MDs suspicious of their grasp.
The only issue selling Otezla is the piss poor coverage. It's double step edited in every single life I sell to. Every single one. The managed care effort is kindergarten from the highest level down to the managed care rep. They were fooled by their success in myeloma and thought they were skilled. No clue how to compete in this market. So if you can adjust your selling to sell a product that's never easy to get, this is fun place and you can bank some coin. If not, stay away.
Oh, and you have to be prepared for the whiners who think their territory is too small. Wimps. Go sell a 6th in class at a big pharma then and quit whining here.
If you find a job where your sales are based upon a quota, you will find over time a sales force devoid of its stars.